Minerva Neurosciences (NERV) Expected to Announce Earnings of -$0.30 Per Share

Equities analysts predict that Minerva Neurosciences (NASDAQ:NERV) will report ($0.30) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Minerva Neurosciences’ earnings. Minerva Neurosciences also posted earnings of ($0.30) per share during the same quarter last year. The firm is expected to report its next earnings report on Thursday, May 3rd.

According to Zacks, analysts expect that Minerva Neurosciences will report full-year earnings of ($1.46) per share for the current year. For the next year, analysts forecast that the company will post earnings of ($1.50) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that that provide coverage for Minerva Neurosciences.

How to Become a New Pot Stock Millionaire

Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Monday, March 12th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.19.

NERV has been the topic of a number of research reports. ValuEngine downgraded shares of Minerva Neurosciences from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. BidaskClub raised shares of Minerva Neurosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. Finally, Zacks Investment Research raised shares of Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $7.25 target price on the stock in a research note on Friday, March 16th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. Minerva Neurosciences has a consensus rating of “Buy” and an average target price of $12.75.

Several hedge funds have recently modified their holdings of NERV. Sterling Capital Management LLC increased its stake in Minerva Neurosciences by 25.2% during the 3rd quarter. Sterling Capital Management LLC now owns 52,135 shares of the biopharmaceutical company’s stock worth $396,000 after buying an additional 10,479 shares during the period. Goldman Sachs Group Inc. increased its stake in Minerva Neurosciences by 47.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 40,835 shares of the biopharmaceutical company’s stock worth $247,000 after buying an additional 13,199 shares during the period. Schwab Charles Investment Management Inc. increased its stake in Minerva Neurosciences by 64.7% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 57,000 shares of the biopharmaceutical company’s stock worth $434,000 after buying an additional 22,400 shares during the period. Bank of New York Mellon Corp increased its stake in Minerva Neurosciences by 33.2% during the 3rd quarter. Bank of New York Mellon Corp now owns 121,152 shares of the biopharmaceutical company’s stock worth $921,000 after buying an additional 30,223 shares during the period. Finally, Ascend Capital LLC increased its stake in Minerva Neurosciences by 4.8% during the 4th quarter. Ascend Capital LLC now owns 819,347 shares of the biopharmaceutical company’s stock worth $4,957,000 after buying an additional 37,659 shares during the period. 70.13% of the stock is currently owned by institutional investors and hedge funds.

Shares of NERV stock opened at $6.90 on Friday. Minerva Neurosciences has a 52 week low of $4.80 and a 52 week high of $11.15. The firm has a market capitalization of $269.31, a PE ratio of -6.39 and a beta of 1.43.

ILLEGAL ACTIVITY NOTICE: “Minerva Neurosciences (NERV) Expected to Announce Earnings of -$0.30 Per Share” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/14/minerva-neurosciences-nerv-expected-to-announce-earnings-of-0-30-per-share.html.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Get a free copy of the Zacks research report on Minerva Neurosciences (NERV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply